UBS Group’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

UBS Group’s Portfolio ARIA Stock Details ARIA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-370,402	Closed	-$4.61M	–	8375
2016 Q4	$4.61M	Buy	370,402 +98,160	+36%	+$1.18M	﹤0.01%	2169
2016 Q3	$3.73M	Buy	272,242 +64,066	+31%	+$643K	﹤0.01%	2293
2016 Q2	$1.54M	Buy	208,176 +82,531	+66%	+$619K	﹤0.01%	2999
2016 Q1	$803K	Sell	125,645 -378,818	-75%	-$2.12M	﹤0.01%	3432
2015 Q4	$3.15M	Buy	504,463 +272,865	+118%	+$1.79M	﹤0.01%	2375
2015 Q3	$1.35M	Sell	231,598 -19,604	-8%	-$151K	﹤0.01%	3091
2015 Q2	$2.08M	Buy	251,202 +27,481	+12%	+$243K	﹤0.01%	2941
2015 Q1	$1.84M	Sell	223,721 -22,887	-9%	-$169K	﹤0.01%	3007
2014 Q4	$1.7M	Buy	+246,608	New	+$1.54M	﹤0.01%	3061

Other funds holding ARIA

FPF

FNY Partners Fund New York $185M AUM 32.57% 1-Year Est. Return

UBS Group's ARIA Position: Q1 2017 in Review

UBS Group sold out of Ariad Pharmaceuticals Inc (ARIA) in Q1 2017, closing a stake of 370,402 shares — an estimated $4.61M sold.

UBS Group first reported a position in ARIA in Q4 2014 and held it in 9 quarters. The position peaked at $4.61M in Q4 2016. 1 fund tracked by Wall St. Rank holds ARIA as of Q1 2017.

UBS Group reported no remaining Ariad Pharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
UBS Group sold 370,402 Ariad Pharmaceuticals Inc shares in Q1 2017, an estimated $4.61M.
UBS Group first reported a position in Ariad Pharmaceuticals Inc in Q4 2014 and held it in 9 quarters.
UBS Group's Ariad Pharmaceuticals Inc position peaked at $4.61M in Q4 2016.
1 fund tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q1 2017.

Based on UBS Group's 13F filing for Q1 2017, filed 12 May 2017.